In the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the use of IO (immunotherapy) in unresectable HCC (uHCC) and take a deep dive into the different treatment options first-line focusing on IO and IO based combinations. Topics include:
Key clinical takeaways:
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/hcc-connect
X: https://x.com/hccconnectinfo
This content is intended for healthcare professionals only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. AstraZeneca has provided a sponsorship grant towards this independent programme.
This podcast is developed by cor2ed.com
Published on November 2024
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
What treatment options are available for patients with metastatic colorectal cancer who have already progressed through multiple lines of therapy? How can we select...
¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de ovario, y cómo podemos solucionarlos? ¿Por qué es importante identificar las alteraciones...
Understanding HER2-low and HER2-ultralow classification in mBC In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of...